Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet

Table 1 Follow-up results of survival status for colorectal can-cer patients with resection plus autelogous tumor cell vaccine from 1993 to 2000

Year	n	Survival period
		0	1	2	3	4	5	6	7
1993-2000	50	50	50	44	39	35	31	31	29
1994-2000	133	133	125	104	94	90	85	75
1995-2000	127	127	126	116	106	98	93
Total	310	310	301	264	239	223	209	106

Table 2 Follow-up results of survival status for colorectal can-cer patients with resection alone from 1993 to 2000

Year	n	Survival period
		0	1	2	3	4	5	6	7
1993-2000	73	73	71	60	54	41	35	34	33
1994-2000	94	94	85	68	56	47	43	43
1995-2000	90	90	84	69	57	50	47
Total	257	257	240	197	167	138	125	77	33

Table 3 Comparison of yearly survival rates of resected colorectal cancer patients in vaccination group and controll group

Year	n	aYearly survival rates (% ± s-x)
		0	1	2	3	4	5
Vaccination group	310	97.05 ± 0.97	84.35 ± 2.10	76.42 ± 3.23	71.12 ± 3.43	66.51 ± 3.84	60.52 ± 4.57
Controll group	257	93.16 ± 1.60	74.83 ± 2.51	62.50 ± 2.06	50.58 ± 1.99	45.57 ± 1.32	44.76 ± 0.81

^aLife table χ² test P < 0.005 of the two groups.

Table 4 TNF staging in colorectal cancer patients with resec-tion plus vaccine group and resection alone group

Treatment	n	TNF stages
		I	II	III	IV
Resection plus vaccine	310	46(14.8%)	121(39%)	80(25.8%)	63(20.3%)
Resection alone	257	55(21.4%)	94(36.6%)	66(25.7%)	42(16.3%)
Total	567	101	215	146	105

Table 5 Comparison of median survival period, mean survival period of resected colorectal cancer patients of vaccina-tion group and controlled group

Treatment method	n	Median survival period (year)	Mean survival period (year)
Resection plus vaccination group	310	> 7a	5.13 ± 0.60b
Resection alone group	257	4.46	4.15 ± 0.60

^bP < 0.01 vs resection alone group.

Table 6 Comparison of fve-year survival rate, survival period of resected colorectal cancer patients in vaccination group with positive and negative DTH reaction

DTH reactions	n	5-year survival cases	Survival rateb	aSurvival period (-x ± s)
Positive group	10	8	80%	4.7 ± 0.67
Negative group	10	3	30%	3.5 ± 1.80

χ² test ^aP < 0.05,

^bP < 0.0 1 vs negative group.

Table 7 The remission rate of late cancer of digestive tract carcinoma treated with NDV vaccine

Types of disease	n	CR(%)	PR(%)	SD(%)	PD(%)	CR+PR(%)
Colorectal cancer	13	1	3	8	0	4
Stomach cancer	6	0	0	5	0	0
Liver caner	4	0	2	1	0	2
Pancreatic head cancer	1	0	0	1	1	0
Gall bladder cancer	1	0	0	1	0	0
Total	25	1(4.00%)	5(20.00%)	16(64.00%)	1(4.00%)	6(24.00%)

Table 8 Comparison of treatment courses and therapeutic ef-fect of colorectal cancer patients with NDV immunotherapy

Group	n	CR	PR	SD	PD	CR+PR
1 Course	6	0	0	5	1	0
> 2 Courses	7	1	3	3	0	4

χ² = 10, P < 0.01.

Table 9 Immunobgice function prior to and after NDV vaccination therapy

Item	n	Before therapy(-x ± s)	After therapy (-x ± s)	P
NK	10	24.65 ± 7.21	36.58 ± 11.87	< 0.05
CD3+	10	67.15 ± 2.43	71.12 ± 2.86	< 0.01
CD4+	10	38.23 ± 3.01	41.62 ± 2.71	< 0.01
CD8+	10	30.55 ± 1.21	29.84 ± 2.43	> 0.05
CD4+/CD8+	10	1.23 ± 0.12	1.41 ± 0.13	< 0.05